Veigen Therapeutics
Biotechnology company developing groundbreaking therapeutic products directed to intracellular targets, founded by researchers at the Harvard T.H. Chan School of Public Health.
Notes
Veigen Therapeutics is a biotechnology company developing groundbreaking therapeutic products directed to intracellular targets. The company is headquartered in Boston, Massachusetts.
The company was founded by Robert Millman and Quan Lu, Ph.D. at the Harvard T.H. Chan School of Public Health. Veigen's approach focuses on developing novel ways to deliver therapeutics to intracellular targets, which are often difficult to access with traditional drug modalities.
Intracellular targeting has the potential to address diseases that have been challenging to treat with conventional approaches, including certain cancers and genetic disorders.
Team
- Robert Millman - Co-founder
- Quan Lu, Ph.D. - Co-founder
- Harvard T.H. Chan School of Public Health faculty
Additional Research Findings
- Portfolio company of Linden Lake Venture Capital
- Focus on intracellular therapeutics
- Harvard T.H. Chan School of Public Health spinout
- Novel drug delivery approaches
- Boston, Massachusetts headquarters
- Founded in 2020
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Linden Lake Venture Capital | New York, New York, USA | generalist | seedseries-a | 1 |